Tweet
SciDirect. Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors
[Source: ScienceDirect, full page: (LINK). Abstract, edited.]
Antiviral Research, Available online 20 November 2013 / In Press, Accepted Manuscript.
Review
Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors
Andy Kilianski, Susan C. Baker
Department of Microbiology and Immunology, Loyola University Chicago Stritch School of Medicine, Maywood, IL 60153
Available online 20 November 2013
Highlights
Abstract
To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-CoV activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of the Middle East respiratory syndrome (MERS)-CoV necessitates adapting methods that have been used to identify antivirals against the severe, acute respiratory syndrome (SARS)-CoV and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on ?From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.?
Keywords: SARS-CoV; MERS-CoV; Entry inhibitors; Replicase inhibitors; Antivirals; pGlo
Corresponding author. Dept. Microbiology and Immunology, Loyola University Chicago Stritch School of Medicine, 2160 S. First Ave., Bldg. 105 Rm 3929, Maywood, IL 60153. Tel.: 708 216 6910.
Copyright ? 2013 Published by Elsevier B.V.
Note to users: Accepted manuscripts are Articles in Press that have been peer reviewed and accepted for publication by the Editorial Board of this journal. They have not yet been copy edited and/or formatted in the journal house style, and may not yet have the full ScienceDirect functionality, e.g., supplementary files may still need to be added, links to references may not resolve yet etc. The text could still change before final publication.
Although accepted manuscripts do not have all bibliographic details available yet, they can already be cited using the year of online publication and the DOI, as follows: author(s), article title, journal (year), DOI. Please consult the journal's reference style for the exact appearance of these elements, abbreviation of journal names and use of punctuation.
When the final article is assigned to an issue of the journal, the Article in Press version will be removed and the final version will appear in the associated published issue of the journal. The date the article was first made available online will be carried over.
-
-------
Antiviral Research, Available online 20 November 2013 / In Press, Accepted Manuscript.
Review
Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors
Andy Kilianski, Susan C. Baker
Department of Microbiology and Immunology, Loyola University Chicago Stritch School of Medicine, Maywood, IL 60153
Available online 20 November 2013
Highlights
- Coronavirus entry, proteolytic processing and RNA synthesis enzymes are attractive targets for antivirals.
- Cell-based screens have been used to identify and evaluate antivirals against SARS-CoV and MERS-CoV.
- New approaches are available to characterize pan-coronavirus inhibitors against CoV proteases.
- Antivirals against SARS-CoV may have efficacy against MERS-CoV and other emerging coronaviruses.
Abstract
To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-CoV activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of the Middle East respiratory syndrome (MERS)-CoV necessitates adapting methods that have been used to identify antivirals against the severe, acute respiratory syndrome (SARS)-CoV and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on ?From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.?
Keywords: SARS-CoV; MERS-CoV; Entry inhibitors; Replicase inhibitors; Antivirals; pGlo
Corresponding author. Dept. Microbiology and Immunology, Loyola University Chicago Stritch School of Medicine, 2160 S. First Ave., Bldg. 105 Rm 3929, Maywood, IL 60153. Tel.: 708 216 6910.
Copyright ? 2013 Published by Elsevier B.V.
Note to users: Accepted manuscripts are Articles in Press that have been peer reviewed and accepted for publication by the Editorial Board of this journal. They have not yet been copy edited and/or formatted in the journal house style, and may not yet have the full ScienceDirect functionality, e.g., supplementary files may still need to be added, links to references may not resolve yet etc. The text could still change before final publication.
Although accepted manuscripts do not have all bibliographic details available yet, they can already be cited using the year of online publication and the DOI, as follows: author(s), article title, journal (year), DOI. Please consult the journal's reference style for the exact appearance of these elements, abbreviation of journal names and use of punctuation.
When the final article is assigned to an issue of the journal, the Article in Press version will be removed and the final version will appear in the associated published issue of the journal. The date the article was first made available online will be carried over.
-
-------